Christine Houston
Directeur/Membre du Conseil chez St. Louis College of Pharmacy
Profil
Christine Houston is currently the Director at St. Louis College of Pharmacy.
Previously, she held positions as Director-Gateway Chapter at Multiple Sclerosis Society, President & Director at CuraScript, Inc., and Senior Vice President-Pharma & Retail Relations at Express Scripts, Inc. From 2016 to 2018, she was the Chief Operating Officer & Executive Vice President at Express Scripts Holding Co. She obtained her undergraduate degree from St. Louis University.
Postes actifs de Christine Houston
| Sociétés | Poste | Début |
|---|---|---|
| St. Louis College of Pharmacy | Directeur/Membre du Conseil | - |
Anciens postes connus de Christine Houston
| Sociétés | Poste | Fin |
|---|---|---|
| EXPRESS SCRIPTS HOLDING CO | Directeur des opérations | 24/01/2018 |
Multiple Sclerosis Society
 Multiple Sclerosis Society Miscellaneous Commercial ServicesCommercial Services The Multiple Sclerosis Society is an organization that aims to find treatments for everyone affected by multiple sclerosis. The non-profit company is based in London, UK. The British company offers award-winning publications, factsheets, and booklets through their online shop. The society conducts surveys to shape the future direction of MS research, with the latest survey held in 2022 with over 6,500 participants. The company's current focus is on the STARMS trial, which compares HSCT with other highly effective treatments for relapsing MS. The treatment involves using chemotherapy to remove harmful immune cells and regrow the immune system using the patient's own stem cells. Nick Moberly has been the CEO of the company since 2019. | Corporate Officer/Principal | - |
CuraScript, Inc.
 CuraScript, Inc. Drugstore ChainsRetail Trade CuraScript provided biopharmaceuticals, complex therapies and related disease treatment services. It offered services for physicians, health plan sponsors, and pharmaceutical manufacturers. The company was founded in 1989 and is headquartered in St. Louis, MO. | President | - |
Express Scripts, Inc.
 Express Scripts, Inc. Drugstore ChainsRetail Trade Express Scripts, Inc. provides pharmacy benefit management services The company was founded by Howard L. Waltman in September 1986 and is headquartered in St. Louis, MO. | Directeur des opérations | - |
Formation de Christine Houston
| St. Louis University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Express Scripts, Inc.
Express Scripts, Inc. Drugstore ChainsRetail Trade Express Scripts, Inc. provides pharmacy benefit management services The company was founded by Howard L. Waltman in September 1986 and is headquartered in St. Louis, MO. | Retail Trade |
Express Scripts Holding Co.
 Express Scripts Holding Co. Insurance Brokers/ServicesFinance Express Scripts Holding Co. operates as a pharmacy benefit management company. It offers opioid management; digital health formulary; therapeutic resource centers; patient assurance program; and diabetes, inflammatory conditions, oncology, and pulmonary solutions. The company was founded in 1986 and is headquartered in St. Louis, MO. | Finance |
CuraScript, Inc.
CuraScript, Inc. Drugstore ChainsRetail Trade CuraScript provided biopharmaceuticals, complex therapies and related disease treatment services. It offered services for physicians, health plan sponsors, and pharmaceutical manufacturers. The company was founded in 1989 and is headquartered in St. Louis, MO. | Retail Trade |
Multiple Sclerosis Society
Multiple Sclerosis Society Miscellaneous Commercial ServicesCommercial Services The Multiple Sclerosis Society is an organization that aims to find treatments for everyone affected by multiple sclerosis. The non-profit company is based in London, UK. The British company offers award-winning publications, factsheets, and booklets through their online shop. The society conducts surveys to shape the future direction of MS research, with the latest survey held in 2022 with over 6,500 participants. The company's current focus is on the STARMS trial, which compares HSCT with other highly effective treatments for relapsing MS. The treatment involves using chemotherapy to remove harmful immune cells and regrow the immune system using the patient's own stem cells. Nick Moberly has been the CEO of the company since 2019. | Commercial Services |